Efficacy of Different Probiotic Protocols in Irritable Bowel Syndrome: A Network Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Jul 7

PMID 31277101

Citations 25

Authors

Ding Liang

Ning Longgui

Xu Guoqiang

Affiliations

Soon will be listed here.

Abstract

Background: Probiotics is a prevalence therapeutic method for irritable bowel syndrome (IBS), but there is lack of comparison in different protocols. We aim to differentiate the reasonable protocols by assessing the efficacy and safety through the combined way of traditional and network meta-analysis.

Method: PubMed, Medline, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials databases were searched from January 2006 to April 2019. The relative risk (RR) with a 95% confidence interval (CI) was used to combine dichotomous data of responders.

Result: Among 14 studies included 1695 patients were identified as suitable for inclusion. The proportion of responders was associated with the administration of multispecies probiotics (RR: 1.39; 95% CI: 1.19-1.61) and the dose of 10∼10 (RR: 2.08; 95% CI: 1.59-2.71). In network meta-analysis, the protocol of DUO had a significant effect for diarrhea type of IBS compared with placebo (RR: 7.46; 95% CI: 2.00-32.23). In the rest of 4 protocols, no significant difference was found in each other except F19 which appears inferior when compared with Pro (RR: 0.16; 95% CI: 0.03-0.88). Meanwhile, Pro showed a superior effect for undifferentiated-type IBS compared with placebo (RR: 7.16; 95% CI: 1.72-29.89). No probiotics-associated severe adverse event was reported in included studies.

Conclusion: Probiotics is a safety choice to improve the overall symptoms for IBS patient. The protocols with suitable dose combined of Lactobacillus and Bifidobacterium can have prepotent effects compared with single species or over-dosage protocols. Network meta-analysis shows that DUO may be the first recommendation for diarrhea-type IBS. In the remaining 4 regimes of this study, Pro has a high rank for undifferentiated-type IBS.

Citing Articles

Network pharmacology integrated with molecular docking and molecular dynamics simulations to explore the mechanism of Shaoyao Gancao Tang in the treatment of asthma and irritable bowel syndrome.

Ren M, Ma J, Qu M Medicine (Baltimore). 2024; 103(50):e40929.

PMID: 39686413 PMC: 11651441. DOI: 10.1097/MD.0000000000040929.

Microbiome-Based Therapeutics for Insomnia.

Li C, Chen S, Wang Y, Su Q Int J Mol Sci. 2024; 25(23).

PMID: 39684918 PMC: 11642687. DOI: 10.3390/ijms252313208.

Synbiotics as Treatment for Irritable Bowel Syndrome: A Review.

Sommermeyer H, Piatek J Microorganisms. 2024; 12(7).

PMID: 39065261 PMC: 11278745. DOI: 10.3390/microorganisms12071493.

Effectiveness of a Balanced Nine-Strain Synbiotic in Primary-Care Irritable Bowel Syndrome Patients-A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial.

Sommermeyer H, Chmielowiec K, Bernatek M, Olszewski P, Kopczynski J, Piatek J Nutrients. 2024; 16(10).

PMID: 38794741 PMC: 11123967. DOI: 10.3390/nu16101503.

Efficacy of Probiotics in Improving Motor Function and Alleviating Constipation in Parkinson's Disease: A Randomized Controlled Trial.

Ghalandari N, Assarzadegan F, Habibi S, Esmaily H, Malekpour H Iran J Pharm Res. 2023; 22(1):e137840.

PMID: 38116573 PMC: 10728848. DOI: 10.5812/ijpr-137840.

References

Mangel A . Personal view: adequate relief as a primary endpoint in irritable bowel syndrome. Aliment Pharmacol Ther. 2006; 23(7):879-81. DOI: 10.1111/j.1365-2036.2006.02839.x. View

Lorenzo-Zuniga V, Llop E, Suarez C, Alvarez B, Abreu L, Espadaler J . I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014; 20(26):8709-16. PMC: 4093724. DOI: 10.3748/wjg.v20.i26.8709. View

Kiefer C, Sturtz S, Bender R . Indirect Comparisons and Network Meta-Analyses. Dtsch Arztebl Int. 2015; 112(47):803-8. PMC: 4678383. DOI: 10.3238/arztebl.2015.0803. View

Lyra A, Hillila M, Huttunen T, Mannikko S, Taalikka M, Tennila J . Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J Gastroenterol. 2017; 22(48):10631-10642. PMC: 5192275. DOI: 10.3748/wjg.v22.i48.10631. View

Liu H, Wu H, Chen Y, Chen Y, Shen X, Liu T . Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. Dig Liver Dis. 2017; 49(4):331-337. DOI: 10.1016/j.dld.2017.01.142. View

Whelan K . Editorial: The importance of systematic reviews and meta-analyses of probiotics and prebiotics. Am J Gastroenterol. 2014; 109(10):1563-5. DOI: 10.1038/ajg.2014.258. View

Mangell P, Nejdfors P, Wang M, Ahrne S, Westrom B, Thorlacius H . Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability. Dig Dis Sci. 2002; 47(3):511-6. DOI: 10.1023/a:1017947531536. View

Whorwell P, Altringer L, Morel J, Bond Y, Charbonneau D, OMahony L . Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006; 101(7):1581-90. DOI: 10.1111/j.1572-0241.2006.00734.x. View

Guglielmetti S, Mora D, Gschwender M, Popp K . Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011; 33(10):1123-32. DOI: 10.1111/j.1365-2036.2011.04633.x. View

10.

Wu J . Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome: facts or myths?. Gastroenterol Hepatol (N Y). 2011; 6(11):705-11. PMC: 3033541. View

11.

Begtrup L, de Muckadell O, Kjeldsen J, Christensen R, Jarbol D . Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol. 2013; 48(10):1127-35. DOI: 10.3109/00365521.2013.825314. View

12.

Quigley E . The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS). J Clin Med. 2018; 7(1). PMC: 5791014. DOI: 10.3390/jcm7010006. View

13.

Irvine E, Tack J, Crowell M, Gwee K, Ke M, Schmulson M . Design of Treatment Trials for Functional Gastrointestinal Disorders. Gastroenterology. 2016; 150(6):1469-1480.e1. DOI: 10.1053/j.gastro.2016.02.010. View

14.

Pinto-Sanchez M, Hall G, Ghajar K, Nardelli A, Bolino C, Lau J . Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017; 153(2):448-459.e8. DOI: 10.1053/j.gastro.2017.05.003. View

15.

Yoon J, Sohn W, Lee O, Lee S, Lee K, Won Jun D . Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2013; 29(1):52-9. DOI: 10.1111/jgh.12322. View

16.

Maukonen J, Satokari R, Matto J, Soderlund H, Mattila-Sandholm T, Saarela M . Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol. 2006; 55(Pt 5):625-633. DOI: 10.1099/jmm.0.46134-0. View

17.

Lovell R, Ford A . Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012; 10(7):712-721.e4. DOI: 10.1016/j.cgh.2012.02.029. View

18.

Irvine E, Whitehead W, Chey W, Matsueda K, Shaw M, Talley N . Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2006; 130(5):1538-51. DOI: 10.1053/j.gastro.2005.11.058. View

19.

Nellesen D, Yee K, Chawla A, Lewis B, Carson R . A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm. 2013; 19(9):755-64. PMC: 10437427. DOI: 10.18553/jmcp.2013.19.9.755. View

20.

Cha B, Jung S, Choi C, Song I, Lee H, Kim H . The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol. 2011; 46(3):220-7. DOI: 10.1097/MCG.0b013e31823712b1. View